Research

Hormonal

GLP-1 agonist use (specifically semaglutide) is associated with a reduction in body mass index (from 34.1 ± 9 to 30.6 ± 6) and a decrease in smoking frequency/amount (by 14.4%) among users in Saudi Arabia.

If you are using GLP-1 agonists like semaglutide for weight loss, this study suggests you may also see a reduction in smoking frequency. However, be aware that cost and side effects are major reasons people stop taking the medication. To maintain weight loss, consistent use and healthy lifestyle habits (diet and exercise) are crucial, as obesity is a chronic condition requiring long-term management.

ModerateSupportsMEDIUM confidence
Importantly, the body mass index reduced from 34.1 ± 9 to 30.6 ± 6, following GLP-1 agonists use... 24.03% of patients on GLP-1 agonists used to smoke cigarettes, and smoking decreased by 14.4% following GLP-1 agonists use.
Amirah Alhowiti et al. · Frontiers in Pharmacology · 2025

Why this rating

Cross-sectional observational study with self-reported data and potential selection bias; not a randomized controlled trial.

Source

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

Amirah Alhowiti et al. · Frontiers in Pharmacology · 2025

DOI 10.3389/fphar.2025.1510554

cross_sectional · n=481Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →